Significant increase in pharmaceutical substances imports this year in Russia

21 August 2017

Russian drugmakers and foreign companies operating in the country have significantly increased the volume of pharmaceutical substances imports this year, a spokesman for Veronika Skvortsova, Russia’s Minister of Health, recently said, reports The Pharma Letter’s local correspondent..

For the six months of 2017, 6,500 tonnes of substances were imported to Russia with a total value of 28.8 billion roubles (~$485 million). This is 16% more than in the same period of last year in value and almost 26% higher in volume terms.

The main reason for this is the decline of the US dollar, compared to the Russian rouble, as well as the growth of local production, including at the facilities of global drugmakers.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK